Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. - Wikidata - awgldk - TriplyDB

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.

http://www.wikidata.org/entity/Q37564751

about

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis Next-generation sequencing: advances and applications in cancer diagnosis The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential The myeloma stem cell concept, revisited: from phenomenology to operational terms TPL2 kinase regulates the inflammatory milieu of the myeloma niche The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma Implications of heterogeneity in multiple myeloma.Serial exome analysis of disease progression in premalignant gammopathies.Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.Curing myeloma at last: defining criteria and providing the evidence.Differential and limited expression of mutant alleles in multiple myeloma.Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.How I treat smoldering multiple myeloma.Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis.Dilemmas in treating smoldering multiple myeloma.Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations Long-term disease control by pomalidomide-/dexamethasone-based therapy in a patient with advanced multiple myeloma: a case report and review of the literature.Pathogenesis beyond the cancer clone(s) in multiple myeloma.Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma RNA-Seq following PCR-based sorting reveals rare cell transcriptional signatures Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).Preclinical animal models of multiple myeloma Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.Leveraging premalignant biology for immune-based cancer prevention.Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice.Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.Incorporating novel agents in the management of elderly myeloma patients.Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.A replicative self-renewal model for long-lived plasma cells: questioning irreversible cell cycle exit.The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.Identification of the potential risk factors for monoclonal gammopathy of undetermined significance of progression.Current and potential epigenetic targets in multiple myeloma.The Tao of myeloma.Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma.

P2860

Q26799104-B33A5361-1BFD-458F-B810-16522B2690E6 Q26991480-D8D009BD-7C2E-44AA-BA11-0D7822009710 Q28073891-D5282EDE-5F1E-43EF-AF81-19A75E0E092F Q28075927-1DC96259-C310-469C-80E4-8F1C904FBFAD Q28076070-854F66AC-F2D3-492B-90D8-482EBD36624D Q33714724-49F12AD1-8049-43F5-8CEC-A482937EDAA4 Q33838260-0ECAC243-7A3F-4FD9-A446-C3965C84B210 Q33914824-47681BE0-0AD0-4C2E-8F18-2A5D45F85E4A Q34079934-F0E90138-463C-4835-ABFC-145737636DA2 Q34479418-FE1134BB-708C-4AB9-9374-CAD528292D59 Q34508313-6863810C-A596-4D72-8D8C-9EE1CFA61460 Q34508343-DFE8CBEC-2F71-421B-83CA-4B96699ED20E Q34525834-76FCE3AC-0431-4607-AE37-3BF31031C9C9 Q34556156-5F6E6E00-55E2-4F43-B1E2-7413CE48B4BE Q34557651-F2C7E58F-EAD8-48F9-9621-0AFF2FEA59EE Q34580094-4C5D35DB-4DF1-4488-890D-0934FE62EDE5 Q34607063-81FE8E4E-CFA2-47AF-92FF-0BE8174BE56B Q34716500-785562A1-3A96-4CD7-9463-FC3CEBED14F7 Q35081172-1BD57354-1229-4A30-8CFC-C6B261BB250D Q35592482-EB6FDC14-2CF2-4BAD-BFBF-6B0FE7381D8C Q35607266-8A61C59D-E7CD-4F0D-8E37-61828387D1BC Q35925252-C7E31608-FAC5-4B90-A47E-D8363E93E51F Q36020424-135DAEC1-ED76-440B-A91A-6E7A7A00C549 Q36306807-3699DE89-CA62-4FF5-B24A-18B9D7DB6B85 Q36561366-91AA39A8-AB8E-42C3-8BD5-ECDFE0012947 Q36916348-626DD048-7F99-458F-B8D1-959F7A18659B Q37304964-C7C92779-2D99-4C03-942E-E98EE9A72E35 Q37402009-A67C59D7-FE0E-4503-B1F0-7D02E6917552 Q37528285-3045772E-1BEF-4259-BF35-447357F51239 Q37593761-C45E29E5-253A-48CD-8C40-2258284FC3ED Q37705811-E42AE604-ED33-4E4B-9415-E4A303066812 Q38146974-EF2621F2-C297-4CDC-8449-221786E8CAE8 Q38151195-832677E4-32C5-44C0-A3E7-0F677419A5DB Q38175395-44AEBD4F-EEBC-45C3-A7A9-050839901A05 Q38192044-F75D90FD-8317-4D94-B498-49B3F0E6D110 Q38199534-335F5F16-0537-468A-BF92-9E4740E18A77 Q38210475-53A8B4CF-8E12-4FE6-B460-2FF22FC8346A Q38237360-7269ED4F-847D-4244-90D4-900186815713 Q38255333-8B0891AA-7947-4301-A3D9-C10A1C4FB7B5 Q38364172-458DD793-3963-4A19-99B3-EC19E0581E0D

P2860

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.

http://www.wikidata.org/entity/Q37564751

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Intraclonal heterogeneity is a ...... elopment of clinical symptoms.

@en

Intraclonal heterogeneity is a ...... elopment of clinical symptoms.

@nl

type

label

Intraclonal heterogeneity is a ...... elopment of clinical symptoms.

@en

Intraclonal heterogeneity is a ...... elopment of clinical symptoms.

@nl

prefLabel

Intraclonal heterogeneity is a ...... elopment of clinical symptoms.

@en

Intraclonal heterogeneity is a ...... elopment of clinical symptoms.

@nl

P1433

Q37564751-CEFBA5C1-1D46-4115-88C8-73650448C460

P1476

Q37564751-DFF23E3C-6F32-40F2-BEF7-A344EC2B1C5F

P2093

Q37564751-27F31C82-0A99-4D7F-B00F-26D5AB44E04C

Q37564751-424E21D5-6B3B-4D0E-91B0-F62CFF889FC2

Q37564751-48E7A55E-0785-42D5-A308-6A5AD3447263

Q37564751-4A99FFE9-53B0-492D-93B2-3664CD50CCC1

Q37564751-5A1A5A63-4086-4370-B81E-67A2DF0107D4

Q37564751-6727A0BD-15D7-4797-A59F-81CCBD3A1C38

Q37564751-6EF03EAB-FB27-4F52-A279-BB79E6AE5032

Q37564751-C2B9E638-CF48-484D-8539-90A6D43BA774

Q37564751-CD24095B-E65D-48A7-96F7-34A65FB00E6A

Q37564751-FBDDCA28-BCA2-4C45-A022-441FE0066732

P2860

Q37564751-0999A3AA-1116-4332-AFD2-68874BF9B693

Q37564751-16F21A7A-2FD6-41CE-AD52-788DE1AD4306

Q37564751-179FABB8-D075-4F82-A6F1-70101337E176

Q37564751-1813BB55-29CD-46AC-82E0-656BE126B784

Q37564751-1AC032B1-4084-4A91-8EFF-B490E22BDDB2

Q37564751-289C0752-DF78-44A0-A699-EAB5FB909092

Q37564751-28A5CEE3-391A-4C3E-894D-65CACA23C04E

Q37564751-2FC10225-25FD-4124-B7ED-6A95E5CEE808

Q37564751-3967B2A6-9D26-4816-B343-FA14D757F029

Q37564751-3AD3F203-B07C-492B-96CE-EA8B4F43BB44

P2888

Q37564751-7456EAC9-D333-463E-8E9F-532E3DB2737C

P304

Q37564751-774E747D-26F6-4E72-8422-793F8FB52358

P31

Q37564751-AA4ECEE7-7295-474F-A4DC-6ED0AC88BF15

P356

Q37564751-8600A3FE-3D15-4177-B8C1-81D96D0818CF

P433

Q37564751-3B954792-3C1C-4070-AED2-9269FC74E871

P478

Q37564751-1CF62CBC-E173-4A95-90FB-B9FC02A1A751

P50

Q37564751-179806FA-12F6-4D4D-A7CF-A59DED201DA1

Q37564751-1F0C4F70-6491-4BBA-ACF8-4512CBF120AC

Q37564751-3374EB28-470F-4E9F-841A-0B1AD7FE1AEF

Q37564751-37AC5D64-9E59-4ABF-B534-B8C16FA10506

Q37564751-52264147-D62B-4120-B423-366A04ECFE83

Q37564751-9BE8AFE7-ED23-431E-BE30-E3066637DD02

Q37564751-C80B71F7-4E7D-47EA-B409-31715062E93C

Q37564751-E0CBB30A-CAD4-4290-95F1-16F2613735C5

P577

Q37564751-36D89E6D-6700-4839-8D95-99B77480E112

P5875

Q37564751-B89090A5-11D9-47E2-B340-36EA00C04C4E

P698

Q37564751-56359194-A285-4289-B167-09298A21B02A

P932

Q37564751-7AB04B07-AEEB-4759-8A29-20AA00C129BB

P356

P1433

P1476

Intraclonal heterogeneity is a ...... elopment of clinical symptoms.

@en

P2093

David Bentley

http://www.w3.org/2001/XMLSchema#string

David C Johnson

http://www.w3.org/2001/XMLSchema#string

David Gonzalez

http://www.w3.org/2001/XMLSchema#string

Faith E Davies

http://www.w3.org/2001/XMLSchema#string

Lisa Murray

http://www.w3.org/2001/XMLSchema#string

Lorenzo Melchor

http://www.w3.org/2001/XMLSchema#string

Lucia Lopez-Corral

http://www.w3.org/2001/XMLSchema#string

Mark Ross

http://www.w3.org/2001/XMLSchema#string

Martin F Kaiser

http://www.w3.org/2001/XMLSchema#string

Sean Humphray

http://www.w3.org/2001/XMLSchema#string

P2860

Intratumor heterogeneity: evolution through space and time

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Massive genomic rearrangement acquired in a single catastrophic event during cancer development

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

Fast and accurate short read alignment with Burrows-Wheeler transform

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads

P2888

P304

384-390

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2013.199

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Ramón García-Sanz

Norma C. Gutiérrez

Brian A. Walker

Christopher P Wardell

Fabio Mirabella

Jesus San Miguel

Gareth J Morgan

Annamaria Brioli

P577

2013-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

244481338

http://www.w3.org/2001/XMLSchema#string

P698

23817176

http://www.w3.org/2001/XMLSchema#string

P932

3916874

http://www.w3.org/2001/XMLSchema#string